Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence.
Pruessmann W, Rytlewski J, Wilmott J, Mihm MC Jr, Attrill GH, Dyring-Andersen B, Fields P, Zhan Q, Colebatch AJ, Ferguson PM, Thompson JF, Kallenbach K, Yusko E, Clark RA, Robins H, Scolyer RA, Kupper TS. Pruessmann W, et al. Among authors: attrill gh. Nat Cancer. 2020 Feb;1(2):197-209. doi: 10.1038/s43018-019-0019-5. Epub 2020 Jan 20. Nat Cancer. 2020. PMID: 33305293 Free PMC article.
Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy.
Attrill GH, Owen CN, Ahmed T, Vergara IA, Colebatch AJ, Conway JW, Nahar KJ, Thompson JF, Pires da Silva I, Carlino MS, Menzies AM, Lo S, Palendira U, Scolyer RA, Long GV, Wilmott JS. Attrill GH, et al. J Immunother Cancer. 2022 Jun;10(6):e004771. doi: 10.1136/jitc-2022-004771. J Immunother Cancer. 2022. PMID: 35688560 Free PMC article.
Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites.
Conway JW, Rawson RV, Lo S, Ahmed T, Vergara IA, Gide TN, Attrill GH, Carlino MS, Saw RPM, Thompson JF, Spillane AJ, Shannon KF, Shivalingam B, Menzies AM, Wilmott JS, Long GV, Scolyer RA, Pires da Silva I. Conway JW, et al. Among authors: attrill gh. J Immunother Cancer. 2022 Sep;10(9):e004884. doi: 10.1136/jitc-2022-004884. J Immunother Cancer. 2022. PMID: 36096531 Free PMC article.
Publisher Correction: Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence.
Pruessmann W, Rytlewski J, Wilmott J, Mihm MC Jr, Attrill GH, Dyring-Andersen B, Fields P, Zhan Q, Colebatch AJ, Ferguson PM, Thompson JF, Kallenbach K, Yusko E, Clark RA, Robins H, Scolyer RA, Kupper TS. Pruessmann W, et al. Among authors: attrill gh. Nat Cancer. 2020 Apr;1(4):470. doi: 10.1038/s43018-020-0049-z. Nat Cancer. 2020. PMID: 35121971 No abstract available.
Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients.
Lee H, Quek C, Silva I, Tasker A, Batten M, Rizos H, Lim SY, Nur Gide T, Shang P, Attrill GH, Madore J, Edwards J, Carlino MS, Guminski A, Saw RPM, Thompson JF, Ferguson PM, Palendira U, Menzies AM, Long GV, Scolyer RA, Wilmott JS. Lee H, et al. Among authors: attrill gh. Oncoimmunology. 2018 Oct 31;8(2):e1537581. doi: 10.1080/2162402X.2018.1537581. eCollection 2019. Oncoimmunology. 2018. PMID: 30713793 Free PMC article.
CD4+ T cell immunity against cutaneous melanoma encompasses multifaceted MHC II-dependent responses.
Bawden EG, Wagner T, Schröder J, Effern M, Hinze D, Newland L, Attrill GH, Lee AR, Engel S, Freestone D, de Lima Moreira M, Gressier E, McBain N, Bachem A, Haque A, Dong R, Ferguson AL, Edwards JJ, Ferguson PM, Scolyer RA, Wilmott JS, Jewell CM, Brooks AG, Gyorki DE, Palendira U, Bedoui S, Waithman J, Hochheiser K, Hölzel M, Gebhardt T. Bawden EG, et al. Among authors: attrill gh. Sci Immunol. 2024 Jan 19;9(91):eadi9517. doi: 10.1126/sciimmunol.adi9517. Epub 2024 Jan 19. Sci Immunol. 2024. PMID: 38241401